Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease
Status:
Completed
Trial end date:
2015-12-14
Target enrollment:
Participant gender:
Summary
This randomized phase III trial is studying low-dose prednisone or methylprednisolone to see
how well they work compared with standard-dose prednisone or methylprednisolone in treating
patients with newly diagnosed acute graft-versus-host disease (GVHD). Glucocorticoids, such
as prednisone or methylprednisolone at a starting dose of 2 mg/kg/day are standard treatment
for acute graft-versus-host disease caused by a donor stem cell transplant. It is not yet
known whether low-dose glucocorticoids are more effective than standard-dose glucocorticoids
in treating acute graft-versus-host-disease